•
Dec 31, 2019

DexCom Q4 2019 Earnings Report

DexCom's revenue increased driven by volume growth and new patient additions, resulting in GAAP profitability.

Key Takeaways

DexCom reported a strong fourth quarter and fiscal year 2019, with revenue growth of 37% in Q4 and 43% for the full year. The company achieved GAAP profitability for the first time and is well-positioned for long-term growth.

Revenue grew 37% versus the same quarter of the prior year to $462.8 million.

U.S. revenue growth of 34% and international revenue growth of 52%.

GAAP operating income of $101.5 million or 21.9% of revenue.

Commenced launch of G6 into Medicare

Total Revenue
$463M
Previous year: $338M
+36.9%
EPS
$0.29
Previous year: $0.14
+107.1%
Gross margin
66.8%
Previous year: 65.9%
+1.4%
Operating margin
21.9%
Gross Profit
$309M
Previous year: $223M
+38.8%
Cash and Equivalents
$446M
Previous year: $1.14B
-60.8%
Free Cash Flow
$99.6M
Previous year: $16M
+522.5%
Total Assets
$2.4B
Previous year: $1.92B
+25.0%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

Dexcom reaffirmed its revenue projection and provided the following gross profit, operating margin, and Adjusted EBITDA margin expectations for full fiscal year 2020:

Positive Outlook

  • Revenue of $1.725 billion to $1.775 billion (17% - 20% growth)
  • Gross profit margin of approximately 64%
  • Non-GAAP operating margin of approximately 13%
  • Non-GAAP adjusted EBITDA margin of approximately 23%

Revenue & Expenses

Visualization of income flow from segment revenue to net income